مجله علوم پزشکی پارس

بررسی خصوصیات جمعیت شناختی و تعداد ماه‌های مصرف قرص‌های هورمونی پیشگیری از بارداری در زنان مبتلا به فیبروآدنوم

نویسندگان

1 استادیار جراحی پلاستیک،دانشگاه علوم پزشکی جهرم، جهرم،ایران

2 مرکز تحقیقات سلامت و بیماری های زنان، دانشگاه علوم پزشکی جهرم، جهرم، ایران

3 مرکز تحقیقات مولفه های اجتماعی نظام سلامت، دانشگاه علوم پزشکی جهرم، جهرم، ایران

چکیده

مقدمه: با توجه به شیوع نسبتاً بالای بیماری‌های خوش‌خیم پستان در زنان و ارتباط هورمونی در بلوغ و تنظیم سرعت رشد سلول‌های اپیتلیالی و استرومائی پستان، توجه هر چه بیشتر به این عوامل هورمونی مهم در کاهش میزان شیوع این بیماری‌ها مؤثر خواهد بود. هدف از مطالعه کنونی بررسی ارتباط میزان مصرف قرص‌های هورمونی پیشگیری از بارداری با شیوع فیبروآدنوم در زنان بیمار و سالم مراجعه کننده به کلینیک سرطان پستان خاتم الانبیا جهرم بود.
روش کار: در این مطالعه توصیفی- تحلیلی، 610 نفر از زنان 20-60 سال مراجعه کننده به کلینیک سرطان پستان خاتم الانبیاء شهرستان جهرم در سال 1398 شرکت کردند. ابزار گردآوری اطلاعات در این مطالعه پرسش نامه بود. تجزیه و تحلیل داده‌ها با کمک نرم‌افزار SPSS نسخه 21 با استفاده از آمار توصیفی و استنباطی انجام شد.
یافته‌ها: سابقه افزایش چربی خون در زنان شرکت‌کننده در مطالعه در  دو گروه دارای فیبروآدنوم و فاقد فیبروآدنوم دارای بیشترین فراوانی بود. هم چنین در گروه دارای فیبروآدنوم، 30.2 درصد از زنان دارای اضافه‌وزن و 10.4 درصد چاق بودند. این در حالی است که در گروه فاقد فیبروآدنوم، 43.7 درصد از زنان دارای اضافه وزن و 24.6 درصد چاق بودند. در رابطه با مصرف داروهای هورمونی، نتایج رگرسیون لجستیک با تعدیل اثر سن و شاخص توده بدن نشان داد که مدت زمان مصرف قرص‌های پیشگیری از بارداری، ( CI=0.55,1.56  :OR=0.93)  با شانس ابتلا به توده‌های خوش‌خیم سینه ارتباط معناداری ندارد (p=0.78).
نتیجه‌گیری: نتایج این مطالعه نشان دادکه مصرف قرص‌های پیشگیری از بارداری ارتباطی با بروز بیماری‌های خوش‌خیم پستان ندارد، اما با توجه به ارتباط مصرف قرص‌های هورمونی با بیماری‌های بدخیم پستان، بهتر است این مطالعه از زوایای دیگر و با تعدیل متغیرهای مخدوش کننده در سطح وسیع تری انجام شود.

کلیدواژه‌ها

عنوان مقاله [English]

Demographic characteristics and number of months of taking hormonal contraceptive pills in women with fibroadenoma

نویسندگان [English]

  • Mojtaba Ghaedi 1
  • Elham Rafie 2
  • navid kalani 3
  • Marzieh Haghbeen 2

1 Assistant Professor of Plastic Surgery, Jahrom University of Medical Sciences, Jahrom, Iran

2 Women’s Health and Disease Research Center, Jahrom University of Medical Sciences, Jahrom, Iran

3 Research center for social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran

چکیده [English]

Introduction: Due to the relatively high prevalence of benign breast diseases in women and the hormonal relationship
in puberty and regulating the growth rate of epithelial cells and stromal cells of the breast, more attention to these effective hormonal factors will be effective in reducing the prevalence of these diseases. The aim of the present study was to investigate the relationship between the use of hormonal contraceptive pills and the prevalence of fibroadenoma in women referred to Khatam al-Anbia Breast Cancer Clinic in Jahrom and healthy women referred to Khatam al-Anbia Clinic in Jahrom
Materials and Methods: In this descriptive-analytical study, 610 women referred to Khatam Al-Anbia Breast Cancer Clinic in Jahrom participated in 2019. The data collection tool in this study was a researcher-made questionnaire that the validity of this questionnaire was determined by 5 professors of the Department of Surgery and Obstetrics and its reliability was determined by Cronbach's alpha test of 85%. Data analysis was performed using SPSS software version 21 and descriptive and inferential statistical tests
Results: 610 women aged 20-60 years who referred to Khatamah Al-Anbia Clinic in Jahrom participated in the study. The history of hyperlipidemia in women participating in the study had the highest frequency in fibroadenoma and non-fibroadenoma groups. Also in the fibroadenoma group, 30.2% of women were overweight and 10.4% obese, while in the group without fibroadenoma, 43.7% of women were overweight and 24.6% were obese. Regarding the use of hormonal drugs, the results of logistic regression by modulating the effect of age and BMI showed that the duration of use of OCP, (OR = 0.93 ,CI= 0.55,1.56) was not significantly associated with the chance of developing benign breast masses
(PV= 0.78).
Conclusion: The results of this study showed that the use of birth control pills (OCP) is not associated with the occurrence of benign breast diseases. However, due to the relationship between the use of hormonal pills or malignant breast diseases, it is better to do this study from other angles and by modifying confounding variables and on a larger scale.

کلیدواژه‌ها [English]

  • OCP
  • Mass
  • Benign
  • Fibro Adenoma
References: 1. Kumar M, Ray K, Harode S, Wagh D .The pattern of benign breast diseases in rural hospital in India. East Cent Afr J Surg. 2010; 15(2): 59-64. 2. Darbre PD. Environmental estrogens, cosmetics and breast cancer. Best Pract Res Clin Endocrinol Metab. 2006; 20: 121-43. 3. Coriaty Nelson Z, Ray RM, Gao DL. Risk factors for fibroadenoma in a cohort of female textile workers in Shanghai, China. Am J Epidemiol. 2002; 156(7):599-605. 4. Santen RJ, Mansel R. Benign breast disorders. N Eng J Med. 2005; 21;353(3):275-85. 5. Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33(10):1128-35. 6. Santen RJ. Benign Breast Disease in Women. Deutsch Arztebl Int. 2019; 116(33):565. 7. Ajmal M, Van Fossen K. Breast Fibroadenoma. StatPearls. Treasure Island FL. StatPearls Publishing LLC; 2020. https://www.ncbi.nlm.nih. gov/books /NBK535345/ 8.Sagar A, Iyengar S, Sikarwar S, Mangal KS. Clinical and Histocytological Correlation of Breast Lesions. IOSR-J Dent Med Sci. 2020;19(5):12-6. 9. Abhijit MG, Anantharaman D, Bhoopal S, Ramanujam R. Benign breast diseases: experience at a teaching hospital in rural India. IJRMS. 2013;1(2):73-8. 10.Berkey CS, Tamimi RM, Rosner B, Frazier AL, Colditz GA. Young women with family history of breast cancer and their risk factors for benign breast disease. Cancer 2012;118(11):2796-803 11.Moore T, Lee AH. Expression of CD34 and bcl‐2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. Histopathol. 2001; 38(1):62-7. 12. Li P, Xiao-Yin T, Cui D, Chi JC, Wang Z, et al. Evaluation of the safety and efficacy of percutaneous radiofrequency ablation for treating multiple breast fibroadenoma. J Cancer Res Ther. 2016; 12:138-42. 13. Panda SK, Patro B, Mishra J, Dora RK, Subudhi BS. Multiple fibroadenomas in bilateral breasts of a 46-year-old Indian woman: A case report. Int J Surg Case Rep 2014;5(5):262-4. 14. Rao S, Latha PS, Ravi A, Thanka J. Ductal carcinoma in a multiple fibroadenoma: diagnostic inaccuracies. J Cancer Res Ther. 2010;6(3):385-7 15. Haaghensen CD. Adenofibroma. In: W.B. Saunders Company (eds). Disease of the Breast. W.B. Saunders Company: Philadelphia, London, Toronto, Mexico City, Rio de Janeiro, Sydney, Tokyo, Honk Kong. Mod Pathol. 2006; 19: 599–606. 16. Carter B. A, Page D L, Schuyler P, Parl FF, Simpson JF, et al. No elevation in long‐term breast carcinoma risk for women with fibro adenomas that contain atypical hyperplasia. Cancer. 2001; 92(1): 30-36. 17. Desai M. Role of obstetrician and gynecologist in the management of breast lump. J obstet Gynecol India. 2003; 53:389-91. 18.Houssami N, Cheung MN, Dixon JM. Fibroadenoma of the breast. Med J Aust. 2001;174(4):185-8. 19.Vera-Sempere FJ, Artes Martínez J. Estrogen receptors and breast fibroadenoma with suspicious traits of malignancy. An Med Interna.1997; 14; 332-6. 20.Sapino A, Bosco M, Cassoni P. Estrogen receptorbeta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol.2006; 19:599-606. 21. Arbabi Bidgoli S, Ahmadi R, Zavarhei MD. Role of hormonal and environmental factors on early incidence of breast cancer in Iran. Sci Total Environ.2010; 408: 4056-61. 22.Lisiane Lopes da C, Milene Cristine P, Mariana de Moura ED, Renata Nascimento de F, Jose do Carmo Lopes M, Maria do Carmo Gouveia P. Benign Breast Disease and Associated Factors in Women Attending in A Public Hospital. Int J New Technol Res. 2016;6:14-8. 23.El-Wakeel H, Umpleby HC. Systematic review of fibroadenoma as a risk factor for breast cancer. Breast. 2003, 12:302–307. 24. Muhammad Aslam H, Saleem SH, Arshad Shaikh H, Shahid N, Mughal A, Umah R. Clinico- pathological profile of patients with breast diseases. Diagn Pathol. 2013;8(77): 2-6. 25. Sezgin G, Coskun M, Apaydin M, Keceli M, Cetinoglu K, Tavusbay C. Interacting Factors of Strain Ratio Values in Fibroadenomas and the Contribution of Color Scale. J Med Ultrasound. 2020; 28(3):169-72. 26. Ali EA, Talaat S. Ultrasound Lexicon in diagnosis and management of breast fibroadenoma: when to follow up and when to biopsy. Egypt J Radiol Nucl. 2020; 51(17): 2-16 27. Lazarus SN, Gouse DHM, Kante DR. A Clinicopathological study of breast lesions in a Tribal population in rural Telangana: A 3-year retrospective analysis. Trop J Pathol Microbiol. 2021;7(5):232-6. 28.Gonenc A, Erten D, Aslan S, Akinci M, Simsek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. J Int Cell Biol. 2006;30:376- 80. 29.Prabakar MS, Prakasam N, Reshma S, Loganathan K, Palani V. A clinical study of serum lipid profile in benign breast disease in a tertiary care hospital. Int Surg J. 2019; 6 (316): 2-4. 30. Khanna AK, Tapadar JK, Khanna HD, Khanna S, Khanna A. Behavior of estrogen receptor, histological correlation and clinical outcome in patients with benign breast disorder. Eur J Surg. 2002; 168:631-4. 31. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Canser Res. 2003; 9:5699–704. 32. Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, et al. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. Int J Cancer. 2019; 15;145(2):370-9. 33.Webb PM, Byrne C, Schnitt SJ, Connolly JL, Jacobs T, Peiro G, et al. Family history of breast cancer, age and benign breast disease. Int J cancer. 2002; 20;100(3):375-8. 34. Bhettani M.K, Mubarik R, Altaf H N, Ahmed Syed M , Tahir AA , Khan M.S , et al. Correlation Between Body Mass Index and Fibroadenoma. Cureus. 2019; 11(7): 5219. 35. Stacey O, Kowdley, Chandru G. Benign Breast Diseases and Body Mass Index: Is There a Correlation? Am Surg. 2014; 80(5):461-65. 36. Bidgoli SA, Eftekhari T. Role of exogenous and endogenous sources of estrogen on the incidence of breast fibroadenoma: case-control study in Iran. Asian Pac J Cancer Prev. 2011;12(5):1289-93. 37. Masoudifard M, Dehghani M, Darooghe L, Riahi H, Lame E. Investigating the factors influencing breast lumps in women referring to health centers in Aran and Bidgol. J Ilam Uni Med Sci. 2017; 25 (1) :103-09 38. Vessey M, Yeates D. Oral contraceptives and benign breast disease: an update of findings in a large cohort study. Contraception. 2007; 76(6):418-24
مجله علوم پزشکی پارس
دوره 20، شماره 1
فروردین 1401
صفحه 8-13